Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: J AAPOS. 2023 Sep 21;27(5):276.e1–276.e8. doi: 10.1016/j.jaapos.2023.07.014

Table 2.

Demographics, patient characteristics, and treatment data in all patients 2–12 years of age

Variable Typically developinga Neurodevelopmental disordersa P valueb
n = 406 n = 54
Age, years 5.36 (4.57, 6.69) 5.37 (4.15, 6.18) 0.505
 Younger group (2–6) 316 (77.8%) 44 (81.5%) 0.664
 Older group (7–12) 90 (22.2%) 10 (18.5%) 0.664
Sex 0.107
 Female 202 (49.8%) 20 (37.0%)
 Male 204 (50.2%) 34 (63.0%)
Race (n = 374) (n = 321) (n = 51) 0.372
 White 241 (74.6%) 41 (80.4%)
 Non-White 80 (24.8%) 10 (19.6%)
Ethnicity (n = 347) (n = 301) (n = 44) 0.984
 Hispanic or Latino 34 (11.2%) 5 (11.4%)
 Not Hispanic or Latino 267 (88.7%) 39 (88.6%)
Family history of amblyopia 130 (31.9%) 22 (40.7%) 0.197
Type of amblyopiac 0.634
 Anisometropic 243 (59.9%) 29 (53.7%)
 Strabismic 85 (20.9%) 12 (22.2%)
 Mixed 78 (19.2%) 13 (24.1%)
Severity of amblyopia 0.273
 Moderate: 20/40 ≤ 20/80 BCVA 263 (66.0%) 31 (57.4%)
 Severe: >20/80 BCVA 138 (34.0%) 23 (42.6%)
Prior amblyopia treatment 153 (37.7%) 24 (44.4%) 0.418
Treatment compliance
 Treated with glasses 380 (93.6%) 48 (88.9%) 0.321
 Median glasses compliance 100% (100%, 100%) 100% (75%, 100%) 0.356
 Treated with patching 328 (80.8%) 40 (74.1%) 0.328
 Median patching compliance 60% (25%, 100%) 50% (20%, 100%) 0.515
 Treated with atropine 98 (24.1%) 12 (22.2%) 0.889
 Median atropine compliance 75% (0%, 100%) 75% (20%, 90%) 0.718

BCVA, best-corrected visual acuity.

a

Data are presented as frequency (percentage) for categorical data and median (25th, 75th percentile) for continuous data.

b

Obtained using the χ2 test, Fisher exact test, or Wilcoxon rank-sum test, as appropriate.

c

Anisometropic: ≥1.00 D of spherical equivalent or ≥1.5 D of astigmatism between eyes. Strabismic: heterotropia upon exam. Mixed: meet criteria for anisometropic and strabismic.